THE FEASIBILITY OF MEASURING BTKI MEDICATION ADHERENCE IN THE TREATMENT OF CLL/SLL USING AN ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) PLATFORM
Author(s)
Mustafa Ascha, PhD1, Ronda Copher, PhD2, Lee Ding, PharmD2, Russell Knoth, PhD3, James Essell, MD4;
1Canopy Care, Austin, TX, USA, 2BeOne Medicines Ltd, San Carlos, CA, USA, 3SNELL Medical Communication, Inc., Montreal, QC, Canada, 4Cincinnatti Cancer Advisors, Cincinnati, OH, USA
1Canopy Care, Austin, TX, USA, 2BeOne Medicines Ltd, San Carlos, CA, USA, 3SNELL Medical Communication, Inc., Montreal, QC, Canada, 4Cincinnatti Cancer Advisors, Cincinnati, OH, USA
OBJECTIVES: Bruton tyrosine kinase inhibitors (BTKis) have transformed management of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). These oral therapies, administered in the outpatient setting, offer significant convenience and efficacy. As with all cancer treatments, these therapies require careful monitoring of side effects to ensure adherence. The Canopy Remote Therapeutic Monitoring (RTM) electronic patient-reported outcomes (ePRO) platform is an electronic health record-integrated cloud-based questionnaire delivered via smartphone/web apps, or interactive voice response (Cherny 2022 DOI:10.1200/OP.22.00180). Real-world evidence on the usefulness of ePROs for measuring medication adherence is limited. This study determined the feasibility of using an ePRO-based platform to measure medication adherence in patients with CLL/SLL treated with a BTKi in a community oncology setting.
METHODS: This was a retrospective study of BTKi treatment-naïve adult patients with CLL/SLL treated with a second-generation BTKi from January 1, 2024 to November 1, 2025. Patients invited to participate in ePRO were included if they submitted at least one ePRO report during treatment. ePRO monitoring began at enrollment and was followed by weekly reminders. The ePRO responses of interest included self-reported missed BTKi doses and reasons for missed medication.
RESULTS: Overall, 241 patients submitted at least one ePRO report, over 65 days of treatment, for 1,749 total reports (median=6/patient). Median age was 72 and 63% were male. Patients reported missing a BTKi dose on 162 (9.3%) reports. Of these, 6.4% missed 1-2 doses and 2.9% had 3+ missed doses. Reasons for missed doses included forgetting to take (n=91, 56.2%), due to doctor’s instructions (n=20, 12.3%), or not feeling well (n=31, 19.1%).
CONCLUSIONS: The study demonstrates it is feasible to record real-time remote medication adherence in patients with CLL/SLL undergoing oral BTKi treatment using the Canopy ePRO-based RTM platform. Limitations include patient self-selection for participation and the retrospective design. Real-time access to patient medication adherence may improve patient outcomes.
METHODS: This was a retrospective study of BTKi treatment-naïve adult patients with CLL/SLL treated with a second-generation BTKi from January 1, 2024 to November 1, 2025. Patients invited to participate in ePRO were included if they submitted at least one ePRO report during treatment. ePRO monitoring began at enrollment and was followed by weekly reminders. The ePRO responses of interest included self-reported missed BTKi doses and reasons for missed medication.
RESULTS: Overall, 241 patients submitted at least one ePRO report, over 65 days of treatment, for 1,749 total reports (median=6/patient). Median age was 72 and 63% were male. Patients reported missing a BTKi dose on 162 (9.3%) reports. Of these, 6.4% missed 1-2 doses and 2.9% had 3+ missed doses. Reasons for missed doses included forgetting to take (n=91, 56.2%), due to doctor’s instructions (n=20, 12.3%), or not feeling well (n=31, 19.1%).
CONCLUSIONS: The study demonstrates it is feasible to record real-time remote medication adherence in patients with CLL/SLL undergoing oral BTKi treatment using the Canopy ePRO-based RTM platform. Limitations include patient self-selection for participation and the retrospective design. Real-time access to patient medication adherence may improve patient outcomes.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR57
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance
Disease
SDC: Oncology, STA: Personalized & Precision Medicine